Publication:
Fertility preservation options in breast cancer patients.

cris.virtualsource.author-orcidfda93f1d-bf45-4e13-99f4-a32401b1f110
datacite.rightsopen.access
dc.contributor.authorKasum, Miro
dc.contributor.authorvon Wolff, Michael
dc.contributor.authorFranulić, Daniela
dc.contributor.authorČehić, Ermin
dc.contributor.authorKlepac-Pulanić, Tajana
dc.contributor.authorOrešković, Slavko
dc.contributor.authorJuras, Josip
dc.date.accessioned2024-10-24T16:45:26Z
dc.date.available2024-10-24T16:45:26Z
dc.date.issued2015-11
dc.description.abstractThe purpose of this review is to analyse current options for fertility preservation in young women with breast cancer (BC). Considering an increasing number of BC survivors, owing to improvements in cancer treatment and delaying of childbearing, fertility preservation appears to be an important issue. Current fertility preservation options in BC survivors range from well-established standard techniques to experimental or investigational interventions. Among the standard options, random-start ovarian stimulation protocol represents a new technique, which significantly decreases the total time of the in vitro fertilisation cycle. However, in patients with oestrogen-sensitive tumours, stimulation protocols using aromatase inhibitors are currently preferred over tamoxifen regimens. Cryopreservation of embryos and oocytes are nowadays deemed the most successful techniques for fertility preservation in BC patients. GnRH agonists during chemotherapy represent an experimental method for fertility preservation due to conflicting long-term outcome results regarding its safety and efficacy. Cryopreservation of ovarian tissue, in vitro maturation of immature oocytes and other strategies are considered experimental and should only be offered within the context of a clinical trial. An early pretreatment referral to reproductive endocrinologists and oncologists should be suggested to young BC women at risk of infertility, concerning the risks and benefits of fertility preservation options.
dc.description.numberOfPages6
dc.description.sponsorshipUniversitätsklinik für Frauenheilkunde
dc.identifier.doi10.7892/boris.77663
dc.identifier.pmid26370157
dc.identifier.publisherDOI10.3109/09513590.2015.1081684
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/139354
dc.language.isoen
dc.publisherInforma Healthcare
dc.relation.ispartofGynecological endocrinology
dc.relation.issn0951-3590
dc.relation.organizationDCD5A442C056E17DE0405C82790C4DE2
dc.subjectBreast cancer
dc.subjectchemotherapy
dc.subjectfertility preservation options
dc.subjectyoung age
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleFertility preservation options in breast cancer patients.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage851
oaire.citation.issue11
oaire.citation.startPage846
oaire.citation.volume31
oairecerif.author.affiliationUniversitätsklinik für Frauenheilkunde
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.description.ispublishedpub
unibe.eprints.legacyId77663
unibe.journal.abbrevTitleGYNECOL ENDOCRINOL
unibe.refereedtrue
unibe.subtype.articlereview

Files

Original bundle
Now showing 1 - 1 of 1
Name:
Kasum.pdf
Size:
228.14 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
publisher
Content:
accepted

Collections